Comparison of Zotarolimus-Eluting and Everolimus-Eluting Coronary Stents | Zendy

Patrick W. Serruys | Zendy; Sigmund Silber | Zendy; Scot Garg | Zendy; RobertJan van Geuns | Zendy; Gert Richardt | Zendy; Paweł Buszman | Zendy; Henning Kelbæk | Zendy; Adrianus J. van Boven | Zendy; Sjoerd H. Hofma | Zendy; Axel Linke | Zendy; Volker Klauß | Zendy; William Wijns | Zendy; Carlos Macaya | Zendy; Philippe Garot | Zendy; Carlo Di Mario | Zendy; Ganesh Manoharan | Zendy; Ran Kornowski | Zendy; Thomas Ischinger | Zendy; Antonio L. Bartorelli | Zendy; Jacintha E. Ronden | Zendy; Marco Bressers | Zendy; Pierre Gobbens | Zendy; Manuela Negoita | Zendy; Frank N. van Leeuwen | Zendy; Stephan Windecker | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Comparison of Zotarolimus-Eluting and Everolimus-Eluting Coronary Stents

Author(s) -

Patrick W. Serruys,

Sigmund Silber,

Scot Garg,

RobertJan van Geuns,

Gert Richardt,

Paweł Buszman,

Henning Kelbæk,

Adrianus J. van Boven,

Sjoerd H. Hofma,

Axel Linke,

Volker Klauß,

William Wijns,

Carlos Macaya,

Philippe Garot,

Carlo Di Mario,

Ganesh Manoharan,

Ran Kornowski,

Thomas Ischinger,

Antonio L. Bartorelli,

Jacintha E. Ronden,

Marco Bressers,

Pierre Gobbens,

Manuela Negoita,

Frank N. van Leeuwen,

Stephan Windecker

Publication year - 2010

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1004130

Subject(s) - zotarolimus , medicine , stent , clinical endpoint , everolimus , myocardial infarction , restenosis , cardiology , target lesion , stenosis , revascularization , surgery , radiology , drug eluting stent , percutaneous coronary intervention , randomized controlled trial

New-generation coronary stents that release zotarolimus or everolimus have been shown to reduce the risk of restenosis. However, it is unclear whether there are differences in efficacy and safety between the two types of stents on the basis of prospectively adjudicated end points endorsed by the Food and Drug Administration.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research